Novo Nordisk Canada Inc. Response to COVID-19 – Supporting Canadians Living with Diabetes... Read More

Health Canada approves fast-acting mealtime insulin, Fiasp®, for children with diabetes... Read More

Novo Nordisk Canada Inc. recognized as one of Greater Toronto's Top Employers for 2020... Read More

Global News

Press releases from the Denmark headquarters.

Media

Visit the pressroom of the website for our headquarters in Denmark where you can access the latest corporate stock exchange announcements, an image library, interim and annual reports and other relevant communication from Novo Nordisk A/S.

For all media inquiries, please contact Corporate Communications:    

Tel: 905-629-6612

Email: KXYH@novonordisk.com

If you have concerns regarding any Novo Nordisk product, please call customer care at 1-800-465-4334 or email nnci-drugsafety@novonordisk.com. In the event of a medical emergency, contact your healthcare professional.